Gilead Sciences isn't letting a few of its own generics interfere with advertising its pan-genotypic hep C drug Epclusa. The Big Biotech is turning to TV again to promote its hep C franchise, this ...

Gilead Sciences said Monday it will launch generic versions of Harvoni and Epclusa, its top-selling hepatitis C drugs. Gilead will sell its chronic hepatitis C generics at a $24,000 list price for the ...

Some Medicare Part D plans did not cover generic versions of pricey hepatitis C drugs in 2019, leaving millions in savings on the table, according to a new watchdog report. The report, released ...

Last September, Gilead made the unexpected move of launching authorized generics to its blockbuster hepatitis C drugs Epclusa and Harvoni, well before their patients expire. Now the copycats have ...

There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several large ...